Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey

Breast

Volumn 17, Issue 5, 2008, Pages 459-463

  Fallowfield, Lesley ^a   Jenkins, Valerie ^a   Coleman, Robert ^b  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adherence; Bisphosphonates; Metastatic bone disease; Oncologists' prescribing preferences

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; TRASTUZUMAB; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEALTH CARE AVAILABILITY; HEALTH SURVEY; HUMAN; HYPOCALCEMIA; INFLUENZA; KIDNEY DYSFUNCTION; MALAISE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL SPECIALIST; NAUSEA; NORMAL HUMAN; ONCOLOGY; PATIENT COMPLIANCE; PATIENT DECISION MAKING; POSTAL MAIL; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; SIDE EFFECT; TREATMENT INDICATION; UNITED KINGDOM;

EID: 53149107499     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.02.009     Document Type: Article

References (11)

1. Coleman R.E. Bisphosphonates in breast cancer. Ann Oncol 16 5 (2005) 687-695
2. Pavlakis N., Schmidt R., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3 (2005) CD003474
3. Bobba R.S., Beattie K., Parkinson B., Kumbhare D., and Adachi J.D. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 29 12 (2006) 1133-1152
4. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 10.1093/annonc/mdm
5. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 5 (2005) 487-497
6. Cramer J.A., Gold D.T., Silverman S.L., and Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 8 (2007) 1023-1031
7. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17 2 (2006) 205-210
8. Atkins L., and Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42 14 (2006) 2271-2276
9. Chlebowski R.T., and Geller M.L. Adherence to endocrine therapy for breast cancer. Oncology 71 1-2 (2006) 1-9
10. Fallowfield L. There's many a slip twixt cup and lip: adherence issues in cancer therapy. Nat Clin Pract Oncol 5 3 (2008) 118-119
11. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl 4 (2004) 28-37